Fig. 3
From: Comparing drug safety of hepatitis C therapies using post-market data
Reporting rates of the top 30 AEs between the two treatment groups
Fig. 3 | BMC Medical Informatics and Decision Making
From: Comparing drug safety of hepatitis C therapies using post-market data
Reporting rates of the top 30 AEs between the two treatment groups